Media release
11 August 2025
Industry first a game changer for underwriting in life insurance
Acenda is reimagining life insurance with an innovative underwriting solution that provides quicker, more streamlined access to cover for Australians.
In an industry-first partnership with UnderwriteMe, medical evidence, including doctors’ reports and blood test results, can now be assessed by Acenda’s underwriting engine, enabling faster approvals for cover.
The collaboration with UnderwriteMe follows Acenda’s award-winning partnership with EQ Pathology. Through this partnership, Acenda has streamlined the underwriting process for doctors by replacing traditional paperwork with digital Personal Medical Attendant Reports (PMARs), pathology reports and medical exam results.
Acenda’s new underwriting initiative with UnderwriteMe completes this process with Australia’s first end to end digital solution in the life insurance industry.
Jane Murray, Chief Operating Officer, who leads Acenda’s underwriting function, said: “Acenda’s partnership with UnderwriteMe is an industry first innovation that transforms the collection and processing of medical information.
“In a groundbreaking initiative, the underwriting process will be fully digitised creating a capability where automated underwriting decisions can occur where medical evidence is required. This will create a seamless experience for customers.”
Gerard Kerr, Acenda’s Chief Executive Individual Business, said: “It is part of Acenda’s commitment to innovation, along with creating speed in our decisions to support our adviser partners and customers, as one of Australia’s leading life insurers.”
Paul Hughes, Chief Revenue and Customer Officer for UnderwriteMe, said: “UnderwriteMe have been proud supporters of Acenda for several years in the Australian market, and this latest innovation is a game changer.
“By leveraging technology to solve critical challenges in secondary evidence underwriting, Acenda are making it easier for Australians to obtain their cover in a swifter and smoother way. We are delighted to have collaborated with Acenda and EQ Pathology in delivering this exciting, industry first innovation.”
In an industry-first partnership with UnderwriteMe, medical evidence, including doctors’ reports and blood test results, can now be assessed by Acenda’s underwriting engine, enabling faster approvals for cover.
The collaboration with UnderwriteMe follows Acenda’s award-winning partnership with EQ Pathology. Through this partnership, Acenda has streamlined the underwriting process for doctors by replacing traditional paperwork with digital Personal Medical Attendant Reports (PMARs), pathology reports and medical exam results.
Acenda’s new underwriting initiative with UnderwriteMe completes this process with Australia’s first end to end digital solution in the life insurance industry.
Jane Murray, Chief Operating Officer, who leads Acenda’s underwriting function, said: “Acenda’s partnership with UnderwriteMe is an industry first innovation that transforms the collection and processing of medical information.
“In a groundbreaking initiative, the underwriting process will be fully digitised creating a capability where automated underwriting decisions can occur where medical evidence is required. This will create a seamless experience for customers.”
Gerard Kerr, Acenda’s Chief Executive Individual Business, said: “It is part of Acenda’s commitment to innovation, along with creating speed in our decisions to support our adviser partners and customers, as one of Australia’s leading life insurers.”
Paul Hughes, Chief Revenue and Customer Officer for UnderwriteMe, said: “UnderwriteMe have been proud supporters of Acenda for several years in the Australian market, and this latest innovation is a game changer.
“By leveraging technology to solve critical challenges in secondary evidence underwriting, Acenda are making it easier for Australians to obtain their cover in a swifter and smoother way. We are delighted to have collaborated with Acenda and EQ Pathology in delivering this exciting, industry first innovation.”